Loading
After an immunotherapy side effect has settled, your team may offer to restart the same treatment. About 3 in 10 people who restart have the same side effect again, and some side effects (such as heart or nerve inflammation, or very severe reactions) usually mean stopping for good. It is a shared decision that weighs the cancer benefit against the risk.
Rechallenge is considered once the toxicity has resolved to grade 1 or less and the patient needs no more than 10 mg prednisone a day (SITC 2021). SITC: after grade 2 irAEs, rechallenge may proceed once resolved or controlled on 10 mg/day or less (LE: 3); after grade 3 to 4, the decision is risk-adjusted (LE: 3). Factors against: severe or life-threatening irAEs, prolonged or multiple immunosuppressants, long prior treatment, and complete response or prolonged benefit. ASCO 2021 (abstract): consider resuming most grade 2 toxicities when grade 1 or less; permanently discontinue after grade 4, except endocrinopathies controlled by hormone replacement. ESE 2022: a controlled endocrinopathy is no contraindication (++00).
Organ rules in SITC: colitis needs a repeat endoscopy before resuming; pneumonitis after grade 2 only after complete resolution (LE: 4); myocarditis, Guillain-Barré syndrome and grade 3 to 4 myasthenia gravis lead to permanent or seriously considered permanent discontinuation. ADQI 2026 supports cautious rechallenge after kidney injury (recurrence under 20%).
Evidence: a WHO pharmacovigilance cohort found the same irAE recurred in 28.8% of informative rechallenges, more often after colitis, hepatitis and pneumonitis and less often after adrenal events; two small SITC-cited series found 26 to 43% recurrence and 13 to 26% new irAEs.
Why: Restarting while the inflammation is still active or on high-dose steroids risks a flare.
“Once the toxicity has sufficiently resolved (generally to grade 1 symptoms or lower with ≤10 mg prednisone equivalents per day), patients may be re-challenged.”
Why: Most moderate side effects can be managed if they return.
“Unless otherwise specified, patients who have experienced grade 2 irAEs may be re-challenged with ICI therapy if their signs and symptoms have resolved or are controlled with ≤10 mg of prednisone (or equivalent) per day”
Why: Severe side effects are more likely to return, but restarting may still be worthwhile for some.
“The decision to re-challenge a patient who has experienced grade 3 or 4 irAEs should be risk-adjusted based on anticipated benefit with therapy versus the potential for toxicity”
Why: Someone whose cancer has already responded well may gain little from restarting and risk a lot.
“Factors that may cause clinicians to lean away from re-challenge include severe or life-threatening irAEs, requirement for prolonged or multiple immunosuppressants, and a history of long-term ICI therapy and/or patients with complete responses or prolonged clinical benefit.”
Why: A hormone shortage that is replaced does not get worse with more immunotherapy.
“We recommend that a controlled endocrinopathy is not a contraindication for initiation and/or continuation of ICI therapy”
European Society of Endocrinology, European Journal of Endocrinology 2022 · ++00
Why: Bowel inflammation can persist without symptoms and is one of the side effects most likely to return.
“Repeat endoscopy should be performed prior to resuming ICI therapy.”
Why: Lung inflammation can recur and is among the commonest to come back.
“If patients have experienced grade 2 pneumonitis, they may be re-challenged with ICIs upon complete resolution of symptoms. These patients should be monitored through more frequent consultations with their physician”
Why: These side effects can be fatal if they return.
“Patients diagnosed with Guillain-Barré syndrome should always permanently discontinue ICI therapy, and should receive IVIG or PLEX with corticosteroid therapy”
Why: Knowing the size of the risk helps the patient decide and spot a recurrence early.
“This cohort study found a 28.8% recurrence rate of the same irAE associated with the discontinuation of ICI therapy after a rechallenge with the same ICI.”
Why: A recurrence caught early is easier to treat.
“Close monitoring for recurrence of diarrhea or colitis symptoms is recommended after re-challenging patients with ICI therapy.”
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
SITC 2021 (full text) gives the clearest rule: rechallenge after grade 2 once resolved or controlled on 10 mg prednisone a day or less (LE: 3), a risk-adjusted decision after grade 3 to 4 (LE: 3), and organ-specific exceptions. ASCO 2021 (abstract) is stricter at the top: permanent discontinuation after grade 4 in general, with controlled endocrinopathies the exception. ESE 2022 grades continuing through a controlled endocrinopathy ++00. ADQI 2026 supports cautious rechallenge after kidney injury. All rest on retrospective series and pharmacovigilance data; there are no randomised trials of rechallenge. ESMO 2022 could not be read.
SITC, Journal for ImmunoTherapy of Cancer 2021 · ASCO, Journal of Clinical Oncology 2021 · European Society of Endocrinology, European Journal of Endocrinology 2022 · Acute Disease Quality Initiative, Journal of the American Society of Nephrology 2026 · JAMA Oncology 2020 · ESMO, Annals of Oncology 2022
Where it differs: Recommends permanent discontinuation after grade 4 toxicities in general, except endocrinopathies controlled by hormone replacement, where SITC leaves grade 3 to 4 as a risk-adjusted decision.
Evidence: Informal consensus of an expert panel after a systematic review; read as abstract only.
Where it differs: A nephrology consensus that supports rechallenge in selected patients after ICI-associated kidney injury, citing recurrence in fewer than 20%.
Evidence: Modified Delphi consensus; read as abstract only.
Acute Disease Quality Initiative, Journal of the American Society of Nephrology 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Rechallenge after grade 2 once resolved or controlled on 10 mg prednisone a day or less | LE: 3 | SITC, Journal for ImmunoTherapy of Cancer 2021 |
| Risk-adjusted rechallenge after grade 3 or 4 | LE: 3 | SITC, Journal for ImmunoTherapy of Cancer 2021 |
| Permanent discontinuation after grade 4, except controlled endocrinopathies “In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, except for endocrinopathies that have been controlled by hormone replacement.” | expert consensus | ASCO, Journal of Clinical Oncology 2021 |
| A controlled endocrinopathy is no contraindication to continuing | ++00 | European Society of Endocrinology, European Journal of Endocrinology 2022 |
| Recurrence of the same irAE after rechallenge “One hundred thirty recurrences (28.8%; 95% CI, 24.8-33.1) of the initial irAE were observed.” | observational (pharmacovigilance cohort) | JAMA Oncology 2020 |
Shares Immune-mediated hepatitis from checkpoint inhibitors, by grade, Immune-related myocarditis from checkpoint inhibitors, Immune-related diarrhoea and colitis from checkpoint inhibitors, by grade, Immune-related pneumonitis from checkpoint inhibitors, by grade and the tags protocol, irae.
Shares Neurological side effects of checkpoint inhibitors: myasthenia gravis, Guillain-Barré syndrome, meningitis and encephalitis, Immune-related myocarditis from checkpoint inhibitors, ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors, Society for Immunotherapy of Cancer and the tags protocol, irae.
Shares Neurological side effects of checkpoint inhibitors: myasthenia gravis, Guillain-Barré syndrome, meningitis and encephalitis, ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors, Society for Immunotherapy of Cancer, Avelumab and the tags protocol, irae.
Shares Immune-related diarrhoea and colitis from checkpoint inhibitors, by grade, Society for Immunotherapy of Cancer, Avelumab, Tremelimumab and the tags protocol, irae.
Shares Neurological side effects of checkpoint inhibitors: myasthenia gravis, Guillain-Barré syndrome, meningitis and encephalitis, Immune-related diarrhoea and colitis from checkpoint inhibitors, by grade, Immune-related pneumonitis from checkpoint inhibitors, by grade, ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors and the tags protocol, irae.
Shares ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors, Society for Immunotherapy of Cancer, Avelumab, Tremelimumab and the tags protocol, irae.
Shares ASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors, Society for Immunotherapy of Cancer, Avelumab, Tremelimumab and the tags protocol, irae.
Shares Immune-related adverse events (irAEs), Ipilimumab, Atezolizumab, Durvalumab and the tag irae.